Senores Pharmaceuticals Jumps 12.82% on Strong Q1 FY26 Results; Stock Hits ₹698.20 Intra-day

Mumbai, July 24, 2025 – Senores Pharmaceuticals Ltd (NSE: SENORES)’s stock price soared by over 12% on Thursday after it released its strong Q1 FY26 results and traded at ₹689.00, up ₹81.05 from the previous close.

Senores is a speciality and complex pharmaceutical company that continues to expand its global reach, particularly in challenging, highly regulated, and competitive markets.

Senores Pharmaceuticals Share Price Performance

As of 11:56 AM IST, the scrip had touched an intraday high of ₹689.00, up 13.31% from its previous close of ₹608.95 on the NSE, placing it among the top gainers for the day. The share opened at ₹649.00, and traded between a high of ₹705.00 and a low of ₹643.65.

The VWAP stands at ₹683.26. The total traded volume is 52.12 lakh shares, worth ₹252.39 crore, and the company’s market capitalisation is ₹3,163.88 crore.

Q1 FY26 Performance: Profit Nearly Doubles YoY

During Q1 FY26, the company recorded an all-time high quarterly income, EBITDA, and net profit driven by solid results from Regulated and Emerging Markets. Total Revenue grew 72% year-on-year to ₹138.0 crore; EBITDA improved 60% year-on-year to ₹34.2 crore; and Profit after Tax almost doubled to ₹21.2 crore, up 95% year-on-year. PAT margin improved to 15.4%. Regulated Market revenue, associated with the record EBITDA, increased 69% year-over-year and contributed significantly to the overall growth and results.

Segment Performance: Regulated Market Revenue Rises 69%

Regulated Markets in Q1 FY26 accounted for ₹90.1 crore (+69% YOY), with an EBITDA margin of 35.5%, representing 65% of total revenue. Emerging Markets increased 32% to ₹29.0 crore. The ‘Others’ segment grew strongly to ₹18.9 crore (+264%) from CDMO/CMO projects.

• Regulated Markets comprised 65% of the company’s revenue.
• The ‘Others’ segment experienced strong growth, primarily driven by contract manufacturing services.

Management Commentary

Swapnil Shah, Managing Director of Senores Pharmaceuticals Ltd, said:

“We have begun FY26 on a strong note across all segments. Our differentiated presence in the US through both retail and government channels provides a strategic moat. CDMO/CMO operations are scaling up with increased contracts, offering revenue visibility. Our Branded Generics business momentum has doubled our monthly run rate over last year. We remain confident of becoming a pan-India player by FY26-end.”

He added that the company generated ₹11 crore in positive operating cash flow during Q1 and is structurally repositioning for long-term growth, anchored around three strategic pillars:

1. ANDA portfolio expansion in Regulated Markets
2. CDMO/CMO segment scale-up
3. Profitability and product portfolio improvement in Emerging Markets

Manufacturing & R&D Capabilities

• 24 own commercial ANDA products and 70 approved ANDAs in the US
• 27 CDMO/CMO commercial products and 53 in the pipeline
• 308 registered products and 719 under registration across 40+ countries
• 4 manufacturing facilities (2 in India, 1 in the US for formulations, 1 USFDA-approved)
• 3 R&D centres (2 in India, 1 US)

Company Background

Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company specialising in niche and complex generics for Regulated and Emerging Markets. It has a diversified portfolio across ANDA, CDMO/CMO, and branded generics segments and operates with regulatory approvals from global bodies, including USFDA and WHO-GMP.

REF: https://nsearchives.nseindia.com/corporate/SENORES_23072025192528_Intimationregardingmediareleasesigned.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations